• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Comprehensive analysis of tumor microenvironment cytokines in Waldenstrom macroglobulinemia identifies CCL5 as a novel modulator of IL-6 activity.全面分析华氏巨球蛋白血症肿瘤微环境细胞因子,鉴定出 CCL5 是一种新型的 IL-6 活性调节剂。
Blood. 2011 Nov 17;118(20):5540-9. doi: 10.1182/blood-2011-04-351742. Epub 2011 Sep 14.
2
IL-21 in the bone marrow microenvironment contributes to IgM secretion and proliferation of malignant cells in Waldenstrom macroglobulinemia.骨髓微环境中的白介素 21 有助于瓦尔登斯特伦巨球蛋白血症中 IgM 的分泌和恶性细胞的增殖。
Blood. 2012 Nov 1;120(18):3774-82. doi: 10.1182/blood-2012-03-419440. Epub 2012 Sep 13.
3
[Cytokine profiles of multiple myeloma and Waldenström macroglobulinemia].[多发性骨髓瘤和华氏巨球蛋白血症的细胞因子谱]
Klin Onkol. 2014;27(1):18-23. doi: 10.14735/amko201418.
4
Bone marrow microenvironment in Waldenstrom's Macroglobulinemia.华氏巨球蛋白血症中的骨髓微环境。
Best Pract Res Clin Haematol. 2016 Jun;29(2):148-155. doi: 10.1016/j.beha.2016.08.016. Epub 2016 Sep 4.
5
The Bone Marrow Microenvironment in Waldenström Macroglobulinemia.华氏巨球蛋白血症中的骨髓微环境
Hematol Oncol Clin North Am. 2018 Oct;32(5):777-786. doi: 10.1016/j.hoc.2018.05.005. Epub 2018 Jul 25.
6
Modulation of the IL-6 Receptor α Underlies GLI2-Mediated Regulation of Ig Secretion in Waldenström Macroglobulinemia Cells.白细胞介素-6受体α的调节是瓦尔登斯特伦巨球蛋白血症细胞中GLI2介导的免疫球蛋白分泌调节的基础。
J Immunol. 2015 Sep 15;195(6):2908-16. doi: 10.4049/jimmunol.1402974. Epub 2015 Aug 3.
7
SDF-1/CXCR4 and VLA-4 interaction regulates homing in Waldenstrom macroglobulinemia.基质细胞衍生因子-1/趋化因子受体4(SDF-1/CXCR4)与极迟抗原-4(VLA-4)的相互作用调节华氏巨球蛋白血症中的归巢。
Blood. 2008 Jul 1;112(1):150-8. doi: 10.1182/blood-2007-12-129395. Epub 2008 Apr 30.
8
Soluble PD-1 ligands regulate T-cell function in Waldenstrom macroglobulinemia.可溶性 PD-1 配体调节华氏巨球蛋白血症中的 T 细胞功能。
Blood Adv. 2018 Aug 14;2(15):1985-1997. doi: 10.1182/bloodadvances.2018021113.
9
Circulating Soluble Receptor Activator of Nuclear Factor Kappa B Ligand and C-C Motif Ligand 3 Correlate With Survival in Patients With Waldenström Macroglobulinemia.循环核因子κB受体激活因子配体和C-C基序配体3与华氏巨球蛋白血症患者的生存率相关。
Clin Lymphoma Myeloma Leuk. 2018 Jun;18(6):431-437. doi: 10.1016/j.clml.2018.03.010. Epub 2018 Mar 31.
10
Hypoxia promotes dissemination and colonization in new bone marrow niches in Waldenström macroglobulinemia.缺氧促进华氏巨球蛋白血症中新骨髓微环境中的播散和定植。
Mol Cancer Res. 2015 Feb;13(2):263-72. doi: 10.1158/1541-7786.MCR-14-0150. Epub 2014 Sep 17.

引用本文的文献

1
Tumor-Associated Macrophage (TAM)-Related Cytokines, sCD163, CCL2, and CCL4, as Novel Biomarkers for Overall Survival and Time to Treatment in Waldenstrom's Macroglobulinemia: Emphasis on Asymptomatic WM.肿瘤相关巨噬细胞(TAM)相关细胞因子、可溶性CD163(sCD163)、趋化因子配体2(CCL2)和趋化因子配体4(CCL4)作为华氏巨球蛋白血症总生存期和治疗时间的新型生物标志物:重点关注无症状性华氏巨球蛋白血症
Cells. 2025 Feb 13;14(4):275. doi: 10.3390/cells14040275.
2
Waldenström's Macroglobulinemia/Lymphoplasmacytic Lymphoma Developing Renal AA Amyloidosis: A Case Report and Literature Review.华氏巨球蛋白血症/淋巴浆细胞淋巴瘤并发肾淀粉样变性A:一例报告及文献综述
Intern Med. 2025 Apr 15;64(8):1199-1204. doi: 10.2169/internalmedicine.4678-24. Epub 2025 Feb 8.
3
Expanded tumor-associated polymorphonuclear myeloid-derived suppressor cells in Waldenstrom macroglobulinemia display immune suppressive activity.华氏巨球蛋白血症中扩增的肿瘤相关多形核骨髓来源的抑制性细胞表现出免疫抑制活性。
Blood Cancer J. 2024 Dec 18;14(1):217. doi: 10.1038/s41408-024-01173-w.
4
Patients with Waldenström macroglobulinemia have impaired platelet and coagulation function.华氏巨球蛋白血症患者的血小板和凝血功能受损。
Blood Adv. 2024 Nov 12;8(21):5542-5555. doi: 10.1182/bloodadvances.2024014190.
5
Personalized neoantigen vaccines as early intervention in untreated patients with lymphoplasmacytic lymphoma: a non-randomized phase 1 trial.个体化新抗原疫苗作为未经治疗的淋巴浆细胞淋巴瘤患者的早期干预:一项非随机 1 期试验。
Nat Commun. 2024 Aug 11;15(1):6874. doi: 10.1038/s41467-024-50880-2.
6
Estrogen Receptor Blockade Potentiates Immunotherapy for Liver Metastases by Altering the Liver Immunosuppressive Microenvironment.雌激素受体阻断通过改变肝脏免疫抑制微环境增强对肝转移的免疫治疗。
Cancer Res Commun. 2024 Aug 1;4(8):1963-1977. doi: 10.1158/2767-9764.CRC-24-0196.
7
Serum CXCL13 level is related to treatment response and predicts disease prognosis in Waldenström macroglobulinemia.血清 CXCL13 水平与治疗反应相关,并可预测华氏巨球蛋白血症的疾病预后。
Ann Hematol. 2024 Sep;103(9):3667-3675. doi: 10.1007/s00277-024-05690-3. Epub 2024 Mar 6.
8
Tumor-associated macrophage polarization in the inflammatory tumor microenvironment.炎症性肿瘤微环境中的肿瘤相关巨噬细胞极化
Front Oncol. 2023 Feb 2;13:1103149. doi: 10.3389/fonc.2023.1103149. eCollection 2023.
9
Spatiotemporal dissection of tumor microenvironment via in situ sensing and monitoring in tumor-on-a-chip.通过在肿瘤芯片中的原位传感和监测对肿瘤微环境进行时空剖析。
Biosens Bioelectron. 2023 Apr 1;225:115064. doi: 10.1016/j.bios.2023.115064. Epub 2023 Jan 5.
10
Nucleic Acid Biomarkers in Waldenström Macroglobulinemia and IgM-MGUS: Current Insights and Clinical Relevance.华氏巨球蛋白血症和IgM单克隆丙种球蛋白病中的核酸生物标志物:当前见解与临床相关性
Diagnostics (Basel). 2022 Apr 12;12(4):969. doi: 10.3390/diagnostics12040969.

本文引用的文献

1
GLI2 transcription factor mediates cytokine cross-talk in the tumor microenvironment.GLI2 转录因子介导肿瘤微环境中的细胞因子串扰。
J Biol Chem. 2011 Jun 17;286(24):21524-34. doi: 10.1074/jbc.M111.234146. Epub 2011 Mar 18.
2
Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage.癌症中的炎症细胞因子:肿瘤坏死因子和白细胞介素 6 领衔主演。
Ann Rheum Dis. 2011 Mar;70 Suppl 1:i104-8. doi: 10.1136/ard.2010.140145.
3
Inflammatory signals regulate hematopoietic stem cells.炎症信号调节造血干细胞。
Trends Immunol. 2011 Feb;32(2):57-65. doi: 10.1016/j.it.2010.12.003. Epub 2011 Jan 11.
4
Blocking interleukin-1β in acute and chronic autoinflammatory diseases.阻断白细胞介素-1β在急性和慢性自身炎症性疾病中的作用。
J Intern Med. 2011 Jan;269(1):16-28. doi: 10.1111/j.1365-2796.2010.02313.x.
5
Interleukin 6/interleukin 6 receptor interaction and its role as a therapeutic target for treatment of cachexia and cancer.白细胞介素 6/白细胞介素 6 受体相互作用及其作为治疗恶病质和癌症的治疗靶点的作用。
Cancer Genomics Proteomics. 2010 Nov-Dec;7(6):287-302.
6
The microenvironment in mature B-cell malignancies: a target for new treatment strategies.成熟B细胞恶性肿瘤中的微环境:新治疗策略的靶点
Blood. 2009 Oct 15;114(16):3367-75. doi: 10.1182/blood-2009-06-225326. Epub 2009 Jul 27.
7
Cytokines in the microenvironment of Waldenström's macroglobulinemia.华氏巨球蛋白血症微环境中的细胞因子
Clin Lymphoma Myeloma. 2009 Mar;9(1):43-5. doi: 10.3816/CLM.2009.n.010.
8
Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications.多发性骨髓瘤中IκB激酶(IKK)抑制的生物学后遗症:治疗意义。
Blood. 2009 May 21;113(21):5228-36. doi: 10.1182/blood-2008-06-161505. Epub 2009 Mar 6.
9
Hedgehog-induced survival of B-cell chronic lymphocytic leukemia cells in a stromal cell microenvironment: a potential new therapeutic target.刺猬因子诱导B细胞慢性淋巴细胞白血病细胞在基质细胞微环境中存活:一个潜在的新治疗靶点。
Mol Cancer Res. 2008 Dec;6(12):1928-36. doi: 10.1158/1541-7786.MCR-08-0142.
10
Bone marrow microenvironment and the identification of new targets for myeloma therapy.骨髓微环境与骨髓瘤治疗新靶点的鉴定
Leukemia. 2009 Jan;23(1):10-24. doi: 10.1038/leu.2008.259. Epub 2008 Oct 9.

全面分析华氏巨球蛋白血症肿瘤微环境细胞因子,鉴定出 CCL5 是一种新型的 IL-6 活性调节剂。

Comprehensive analysis of tumor microenvironment cytokines in Waldenstrom macroglobulinemia identifies CCL5 as a novel modulator of IL-6 activity.

机构信息

Schulze Center for Novel Therapeutics, Mayo Clinic, Rochester, MN 55905, USA.

出版信息

Blood. 2011 Nov 17;118(20):5540-9. doi: 10.1182/blood-2011-04-351742. Epub 2011 Sep 14.

DOI:10.1182/blood-2011-04-351742
PMID:21921047
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3217355/
Abstract

Although proinflammatory and chemotactic cytokines can profoundly affect the tumor microenvironment, and many of them have been shown to have therapeutic efficacy in preclinical models, the role of these molecules in Waldenström macroglobulinemia (WM) remains poorly understood. In this study, simultaneous analysis of WM patient sera and bone marrow biopsies identified a set of dysregulated cytokines including CCL5, G-CSF, and soluble IL-2 receptor, that were significantly elevated in WM patients whereas IL-8 and EGF levels were significantly lower in these patients compared with healthy controls. Interestingly, CCL5 levels positively correlated with features of disease aggressiveness such as elevated IgM levels and bone marrow involvement. Functional analysis of tumor microenvironment revealed a functional correlation between CCL5 levels and IL-6 levels, a proinflammatory cytokine with an important role in normal and malignant B-cell biology. Furthermore, CCL5 stimulated IL-6 secretion in WM stromal cells resulting in increased IgM secretion by WM malignant cells via the JAK/STAT signaling pathway. Thus, together these results define a novel signaling network in the WM tumor microenvironment controlling IgM secretion and suggest CCL5 as a potential target for the treatment of this disease.

摘要

虽然促炎细胞因子和趋化因子可以深刻影响肿瘤微环境,并且其中许多因子在临床前模型中显示出治疗效果,但这些分子在华氏巨球蛋白血症(WM)中的作用仍知之甚少。在这项研究中,同时分析 WM 患者的血清和骨髓活检,确定了一组失调的细胞因子,包括 CCL5、G-CSF 和可溶性 IL-2 受体,这些细胞因子在 WM 患者中显著升高,而 IL-8 和 EGF 水平在这些患者中明显低于健康对照组。有趣的是,CCL5 水平与疾病侵袭性特征呈正相关,如升高的 IgM 水平和骨髓受累。肿瘤微环境的功能分析显示,CCL5 水平与促炎细胞因子 IL-6 水平之间存在功能相关性,IL-6 在正常和恶性 B 细胞生物学中具有重要作用。此外,CCL5 刺激 WM 基质细胞分泌 IL-6,导致 WM 恶性细胞通过 JAK/STAT 信号通路增加 IgM 分泌。因此,这些结果共同定义了 WM 肿瘤微环境中的一个新的信号网络,控制 IgM 的分泌,并表明 CCL5 可能是治疗这种疾病的潜在靶点。